for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

79.83USD

Change

0.62(+0.78%)

Volume

2,006,301

Today's Range

79.33

 - 

80.60

52 Week Range

65.26

 - 

92.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
79.21
Open
79.50
Volume
2,006,301
3M AVG Volume
169.58
Today's High
80.60
Today's Low
79.33
52 Week High
92.55
52 Week Low
65.26
Shares Out (MIL)
2,529.24
Market Cap (MIL)
201,909.30
Forward P/E
--
Dividend (Yield %)
3.06

Next Event

Q3 2020 Merck & Co Inc Earnings Call

Latest Developments

More

Merck Announces Positive Topline Results From Two Additional Phase 3 Adult Studies Evaluating V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine

FDA Approves Expanded Indication For Merck's Keytruda In Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Merck Announces Week 96 Data From Phase 2B Study Evaluating Islatravir In Combination With Doravirine In Adults With Hiv1 Infection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.00 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

40.1K

2018

42.3K

2019

46.8K

2020(E)

48.0K
EPS (USD)

2017

3.980

2018

4.340

2019

5.190

2020(E)

5.709
Price To Earnings (TTM)
19.34
Price To Sales (TTM)
4.28
Price To Book (MRQ)
7.30
Price To Cash Flow (TTM)
14.22
Total Debt To Equity (MRQ)
111.69
LT Debt To Equity (MRQ)
94.62
Return on Investment (TTM)
15.97
Return on Equity (TTM)
12.09

Latest News

Latest News

Bristol Myers' Opdivo succeeds in late-stage lung cancer trial

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial. Significantly more non-small cell lung cancer (NSCLC) patients receiving...

Bristol Myers expands heart drug business with $13 billion deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

U.S. drugmaker Merck's research chief Roger Perlmutter to retire

Merck & Co Inc's Roger Perlmutter, a force behind the success of blockbuster cancer drug Keytruda, will retire after seven years at the helm of the company's research and development division, the U.S. drugmaker said on Friday.

U.S. drugmaker Merck's research chief Roger Perlmutter to retire

U.S. drugmaker Merck & Co Inc said on Friday its research chief Roger Perlmutter will retire at the end of the year.

AstraZeneca-Merck's Lynparza wins EU panel recommendation for cancer treatments

A European regulatory panel has recommended the approval of Lynparza, a blockbuster cancer treatment developed by AstraZeneca Plc and Merck & Co Inc, to treat two separate forms of cancer.

Merck to buy $1 bln stake in Seattle Genetics, co-develop cancer therapy

Drugmaker Merck & Co Inc would buy $1 billion worth of equity stake in Seattle Genetics's common stock, the companies said on Monday.

Merck to buy $1 billion equity stake in Seattle Genetics

Merck & Co Inc said on Monday it would buy $1 billion worth of equity stake in Seattle Genetics's common stock.

Merck starts recruitment for COVID-19 vaccine trial

U.S. drugmaker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov.

Merck starts recruitment for COVID-19 vaccine human trial

U.S. drugmaker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov.

BRIEF-Merck & Co Says Not Opposed To Partnering In The HIV Space And Are Exploring All Possibilities- Conf.Call

* SAYS NOT OPPOSED TO PARTNERING IN THE HIV SPACE AND ARE EXPLORING ALL POSIIBILITIES- CONF.CALL Further company coverage:

Merck CEO sees human trials for COVID-19 vaccine candidate 'fairly soon'

Merck aims to start human trials on one of its COVID-19 vaccine candidates "fairly soon," with a second vaccine candidate likely to begin trials later this year, Chief Executive Kenneth Frazier said on Thursday.

Merck to move COVID-19 treatment into large trials, sees sales recovering this year

Merck & Co <MRK.N> on Friday said it plans to advance an antiviral treatment for COVID-19 into large studies in the coming weeks, and it forecast a more limited hit to full-year sales and profit from coronavirus lockdowns than it previously expected.

Merck plans large trials of antiviral COVID-19 drug in September

Drugmaker Merck & Co said on Friday it plans to start two large pivotal trials in September on the experimental oral antiviral COVID-19 drug it is developing with privately held Ridgeback Biotherapeutics.

Merck quarterly sales fall 7.6% as pandemic cuts doctor visits

Merck & Co Inc reported a 7.6% fall in second-quarter sales on Friday as a drop in visits to doctors' offices because of the COVID-19 pandemic hurt sales of several important drugs.

Moderna, Merck say they will not limit price of coronavirus vaccines to company cost

Moderna Inc and Merck & Co on Tuesday told a U.S. Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.

Merck CEO says raising COVID-19 vaccine hopes 'a grave disservice' - report

COVID-19 vaccines under development are not guaranteed to work and people who say to expect a vaccine before year-end are doing a "grave disservice to the public," Merck & Co Inc's <MRK.N> chief said, according to an interview published on a Harvard Business School website...

BRIEF-Merck Animal Health Receives U.S. FDA Approval Of Bravecto® Monthly Chews

* MERCK ANIMAL HEALTH RECEIVES U.S. FDA APPROVAL OF BRAVECTO® (FLURALANER) MONTHLY CHEWS

BRIEF-FDA Grants Priority Review To Merck's Supplemental Biologics License Application For Keytruda (Pembrolizumab) For Second-Line Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

* FDA GRANTS PRIORITY REVIEW TO MERCK’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR KEYTRUDA® (PEMBROLIZUMAB) FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

BRIEF-Merck & Co Says Deborah H. Telman Appointed As General Counsel For Organon & Co.

* MERCK ANNOUNCES APPOINTMENT OF ORGANON & CO. GENERAL COUNSEL

BRIEF-Zymeworks & Merck Sign New License Agreement

* ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up